Navigation Links
Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
Date:6/29/2009

XIANYANG, China, June 29 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it began construction of its raw material processing facility.

Biostar has finished the engineering design and commenced construction for its new raw material processing facility which is expected to be completed in the fourth quarter of 2009.

The raw material processing facility is part of the Company's herbal plantation base. In the herbal plantation base, twelve most widely used medicinal Chinese herbs including Ginkgo, Prickly Ash, Red Sage Root, Schisandra Chinensis, Eucommia were planted, occupying 330,000 square meters. With a favorable climate benefiting the herb yield, the Company expects an initial harvest in September 2009. Approximately 15% of the harvested herbs will be used as raw material reserves for the Company's own production which is expected to lower its production costs while reducing its dependence on third-party suppliers. The remaining 85% will be sold to other pharmaceutical companies, wholesalers and retailers which generates additional revenue for the Company.

"The building of our herbal plantation base represents a key component of our strategic plan and will diversify and increase our revenue. The raw material processing facility enables us to closely control our product quality and ensure we have sufficient supply of key raw materials to meet our growth objectives," said Mr. Wang Ronghua, Chairman and CEO of Biostar Pharmaceuticals, Inc. "We are on track to complete the raw material processing facility in the fourth quarter of 2009. We expect this project to further increase our gross margin and provide incremental revenue for year 2009 and beyond."'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Biostar Pharmaceuticals, Inc. Completes 8.6-Acre Land Purchase to House New Raw Materials Processing Plant
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
7. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
8. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
9. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
10. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... ... president of the National Dental Association (NDA) at 6 p.m. on December 5 at the ... ... will be installed as the 86th president of the National Dental Association (NDA) at 6 ...
... ... N.Y. Times #1 best-seller KNOCKOUT , ... Cornwall, NY (PRWEB) December 2, 2009 -- In her new book KNOCKOUT, Interviews ... Place, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments--treatments that ...
... Award-winning author ... from Patients on Becoming a Doctor, that traces his wild path through the third year ... ... point or another, either find themselves dressed in a tiny hospital gown or staring at ...
... , , ... syndicated radio show, Dr. Rafael Pelayo, Associate Professor at the Stanford ... Ecotones Duet Sleep Sound Machine as part of a healthy sleep ... minimal use of drugs. , "Background noise is a problem for ...
... 2 A randomized, controlled study comparing standard conservative therapy ... painful herniated disc revealed that while both treatments help patients ... free up to two years later. Results of the study, ... annual meeting of the Radiological Society of North America (RSNA). ...
... , SEATTLE, Dec. 2 Cell Therapeutics, Inc. ... M.D. of St. George,s Hospital, University of London, the lead ... data on the pixantrone phase III trial in relapsed/refractory aggressive ... American Society of Hematology on Saturday, December 5, 2009 in ...
Cached Medicine News:Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 2Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 3Health News:New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 4
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... participate in controversial debate over effects of ... Simvastatin vs. Ezetimibe/Simvastatin, ... medical professionals, will air on XM Satellite Radio Channel,157 ... a candid medical,discussion on the much talked-about ENHANCE (Effect ...
... the Addition of L-MTP-PE to, Chemotherapy ... Osteosarcoma Patients, IRVINE, Calif., Feb. 4 ... the Journal of Clinical Oncology (JCO) has,published findings ... entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to,Chemotherapy ...
Cached Medicine Technology:ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7
... leads are small profile endocardial permanent pacing ... a lead body size of only 4.8 ... 7 F, the Physique lead is the ... Available in both straight and pre-formed J ...
Used with Temporary Myocardial Heartwires....
Used with permanent pacing leads....
Suture sleeve for permanent pacing leads....
Medicine Products: